{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:32:05Z","timestamp":1786375925804,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10928-026-10034-x","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:38:10Z","timestamp":1782412690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9099-5177","authenticated-orcid":false,"given":"Paridhi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-7113","authenticated-orcid":false,"given":"Vivaswath S.","family":"Ayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"6","key":"10034_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, Cho HJ, Parekh SS, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez LJ, Thibaud S, Jagannath S, Chari A (2023) IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov 4(6):440\u2013451. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0049","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10034_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103710","volume":"24","author":"MG Danieli","year":"2025","unstructured":"Danieli MG, Antonelli E, Gammeri L, Longhi E, Cozzi MF, Palmeri D, Gangemi S, Shoenfeld Y (2025) Intravenous immunoglobulin as a therapy for autoimmune conditions. Autoimmun Rev 24(1):103710. https:\/\/doi.org\/10.1016\/j.autrev.2024.103710","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10034_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359(3):242\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa0707894","journal-title":"N Engl J Med"},{"issue":"1","key":"10034_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"M Berger","year":"2004","unstructured":"Berger M (2004) Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112(1):1\u20137. https:\/\/doi.org\/10.1016\/j.clim.2004.02.002","journal-title":"Clin Immunol"},{"issue":"3","key":"10034_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","volume":"135","author":"HW Eijkhout","year":"2001","unstructured":"Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT, Inter-University Working Party for the Study of Immune D (2001) The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135(3):165\u2013174. https:\/\/doi.org\/10.7326\/0003-4819-135-3-200108070-00008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10034_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s0022-3476(99)70246-5","volume":"134","author":"P Quartier","year":"1999","unstructured":"Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI, Le Deist F, de Saint Basile G, Fischer A (1999) Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 134(5):589\u2013596. https:\/\/doi.org\/10.1016\/s0022-3476(99)70246-5","journal-title":"J Pediatr"},{"key":"10034_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","volume":"12","author":"M Raghavan","year":"1996","unstructured":"Raghavan M, Bjorkman PJ (1996) Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12:181\u2013220. https:\/\/doi.org\/10.1146\/annurev.cellbio.12.1.181","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"11","key":"10034_CR8","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI107116","volume":"51","author":"EA Jones","year":"1972","unstructured":"Jones EA, Waldmann TA (1972) The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51(11):2916\u20132927. https:\/\/doi.org\/10.1172\/JCI107116","journal-title":"J Clin Invest"},{"key":"10034_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540","journal-title":"Front Immunol"},{"issue":"9","key":"10034_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10034_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","volume":"5","author":"LJ Blumberg","year":"2019","unstructured":"Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A, Cheung J, Mahmood A, Del Tito B, Graydon JS, Stolz LE, Bitonti A, Purohit S, de Graaf D, Kacena K, Andersen JT, Christianson GJ, Roopenian DC, Hubbard JJ, Gandhi AK, Lasseter K, Pyzik M, Blumberg RS (2019) Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv 5(12):eaax9586. https:\/\/doi.org\/10.1126\/sciadv.aax9586","journal-title":"Sci Adv"},{"key":"10034_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","volume":"5","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke SQ, Kuijpers TW (2014) Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 5:674. https:\/\/doi.org\/10.3389\/fimmu.2014.00674","journal-title":"Front Immunol"},{"issue":"10","key":"10034_CR13","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS (2015) FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol 194(10):4595\u20134603. https:\/\/doi.org\/10.4049\/jimmunol.1403014","journal-title":"J Immunol"},{"key":"10034_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","volume":"91","author":"JT Sockolosky","year":"2015","unstructured":"Sockolosky JT, Szoka FC (2015) The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 91:109\u2013124. https:\/\/doi.org\/10.1016\/j.addr.2015.02.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10034_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","volume":"3","author":"TT Kuo","year":"2011","unstructured":"Kuo TT, Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3(5):422\u2013430. https:\/\/doi.org\/10.4161\/mabs.3.5.16983","journal-title":"MAbs"},{"issue":"6","key":"10034_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1006\/jaut.1993.1057","volume":"6","author":"PL Masson","year":"1993","unstructured":"Masson PL (1993) Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 6(6):683\u2013689. https:\/\/doi.org\/10.1006\/jaut.1993.1057","journal-title":"J Autoimmun"},{"issue":"11","key":"10034_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103451","volume":"22","author":"MG Danieli","year":"2023","unstructured":"Danieli MG, Antonelli E, Auria S, Buti E, Shoenfeld Y (2023) Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev 22(11):103451. https:\/\/doi.org\/10.1016\/j.autrev.2023.103451","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10034_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","volume":"22","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC, Meisel A (2022) Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Rev Neurother 22(4):313\u2013318. https:\/\/doi.org\/10.1080\/14737175.2022.2057223","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10034_CR19","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/TP.0000000000002165","volume":"102","author":"YD Muller","year":"2018","unstructured":"Muller YD, Aubert JD, Vionnet J, Rotman S, Sadallah S, Aubert V, Pascual M (2018) Acute antibody-mediated rejection 1 week after lung transplantation successfully treated with eculizumab, intravenous immunoglobulins, and rituximab. Transplantation 102(6):e301\u2013e303. https:\/\/doi.org\/10.1097\/TP.0000000000002165","journal-title":"Transplantation"},{"issue":"11","key":"10034_CR20","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","volume":"99","author":"AA Vo","year":"2015","unstructured":"Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, Reinsmoen N, Peng A, Villicana R, Jordan SC (2015) A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99(11):2356\u20132363. https:\/\/doi.org\/10.1097\/TP.0000000000000741","journal-title":"Transplantation"},{"issue":"1","key":"10034_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D\u2019Souza A, Shah N, Chakraborty R, Shah MR, Schinke C (2025) Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J 15(1):74. https:\/\/doi.org\/10.1038\/s41408-025-01282-0","journal-title":"Blood Cancer J"},{"issue":"5","key":"10034_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","volume":"39","author":"T Shastri","year":"2025","unstructured":"Shastri T, Trabolsi A, Arumov A, Schatz JH (2025) Bispecific antibodies in hematologic malignancies: attacking the frontline. BioDrugs 39(5):793\u2013814. https:\/\/doi.org\/10.1007\/s40259-025-00735-z","journal-title":"BioDrugs"},{"issue":"6","key":"10034_CR23","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1055\/s-0037-1613331","volume":"88","author":"RJ Hansen","year":"2002","unstructured":"Hansen RJ, Balthasar JP (2002) Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 88(6):898\u2013899","journal-title":"Thromb Haemost"},{"issue":"6","key":"10034_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jps.20828","volume":"96","author":"R Deng","year":"2007","unstructured":"Deng R, Balthasar JP (2007) Pharmacokinetic\/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci 96(6):1625\u20131637. https:\/\/doi.org\/10.1002\/jps.20828","journal-title":"J Pharm Sci"},{"issue":"6","key":"10034_CR25","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/jps.10364","volume":"92","author":"RJ Hansen","year":"2003","unstructured":"Hansen RJ, Balthasar JP (2003) Pharmacokinetic\/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92(6):1206\u20131215. https:\/\/doi.org\/10.1002\/jps.10364","journal-title":"J Pharm Sci"},{"issue":"1","key":"10034_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.xphs.2018.10.067","volume":"108","author":"T Li","year":"2019","unstructured":"Li T, Balthasar JP (2019) Development and evaluation of a physiologically based pharmacokinetic model for predicting the effects of anti-FcRn therapy on the disposition of endogenous IgG in humans. J Pharm Sci 108(1):714\u2013724. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.067","journal-title":"J Pharm Sci"},{"issue":"10","key":"10034_CR27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/psp4.12847","volume":"11","author":"SN Salerno","year":"2022","unstructured":"Salerno SN, Deng R, Kakkar T (2022) Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency. CPT Pharmacometrics Syst Pharmacol 11(10):1316\u20131327. https:\/\/doi.org\/10.1002\/psp4.12847","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10034_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","volume":"85","author":"L Vlam","year":"2014","unstructured":"Vlam L, Cats EA, Willemse E, Franssen H, Medic J, Piepers S, Veldink JH, van den Berg LH, van der Pol WL (2014) Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 85(10):1145\u20131148. https:\/\/doi.org\/10.1136\/jnnp-2013-306227","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10034_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, de Gelr J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC (2009) Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2010Barr\u00e9 syndrome. Ann Neurol 66(5):597\u2013603. https:\/\/doi.org\/10.1002\/ana.21737","journal-title":"Ann Neurol"},{"issue":"7","key":"10034_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/08916930600972016","volume":"39","author":"JC Bystryn","year":"2006","unstructured":"Bystryn JC, Jiao D (2006) IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39(7):601\u2013607. https:\/\/doi.org\/10.1080\/08916930600972016","journal-title":"Autoimmunity"},{"issue":"2","key":"10034_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, Matsuzaki Y, Ohtsuka M, Fujiwara H, Furuta J, Tago O, Yamagami J, Tanikawa A, Uhara H, Morita A, Nakanishi G, Tani M, Aoyama Y, Makino E, Muto M, Manabe M, Konno T, Murata S, Izaki S, Watanabe H, Yamaguchi Y, Matsukura S, Seishima M, Habe K, Yoshida Y, Kaneko S, Shindo H, Nakajima K, Kanekura T, Takahashi K, Kitajima Y, Hashimoto K, Bullous Pemphigoid Study G (2017) A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci 85(2):77\u201384. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.11.003","journal-title":"J Dermatol Sci"},{"issue":"9","key":"10034_CR32","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1111\/ajt.15922","volume":"20","author":"SC Jordan","year":"2020","unstructured":"Jordan SC, Kucher K, Bagger M, Hockey HU, Wagner K, Ammerman N, Vo A (2020) Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transpl 20(9):2581\u20132588. https:\/\/doi.org\/10.1111\/ajt.15922","journal-title":"Am J Transpl"},{"issue":"1","key":"10034_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk N (2024) Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv 8(1):194\u2013206. https:\/\/doi.org\/10.1182\/bloodadvances.2023011658","journal-title":"Blood Adv"},{"issue":"4","key":"10034_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","volume":"17","author":"S Girgis","year":"2022","unstructured":"Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y (2022) Translational modeling predicts efficacious therapeutic dosing range of Teclistamab for multiple myeloma. Target Oncol 17(4):433\u2013439. https:\/\/doi.org\/10.1007\/s11523-022-00893-y","journal-title":"Target Oncol"},{"issue":"9","key":"10034_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE (2007) Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 47(9):1119\u20131128. https:\/\/doi.org\/10.1177\/0091270007305297","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10034_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1385\/CRIAI:29:3:207","volume":"29","author":"HU Lutz","year":"2005","unstructured":"Lutz HU, Spath PJ (2005) Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation. Clin Rev Allergy Immunol 29(3):207\u2013212. https:\/\/doi.org\/10.1385\/CRIAI:29:3:207","journal-title":"Clin Rev Allergy Immunol"},{"key":"10034_CR37","doi-asserted-by":"publisher","unstructured":"Paridhi Gupta JZ, Angelia S, Wang E, Lam Y, Xiong, Jocelyn H, Leu W, Wang MN, Samtani, Vivaswath S (2024) Ayyar. Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases. In: American Conference of Pharmacometrics, Phoenix, Arizona, USA. https:\/\/doi.org\/10.70534\/ANMU4976","DOI":"10.70534\/ANMU4976"},{"issue":"10","key":"10034_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/psp4.12461","volume":"8","author":"HM Jones","year":"2019","unstructured":"Jones HM, Zhang Z, Jasper P, Luo H, Avery LB, King LE, Neubert H, Barton HA, Betts AM, Webster R (2019) A physiologically-based pharmacokinetic model for the prediction of monoclonal antibody pharmacokinetics from in vitro data. CPT Pharmacometrics Syst Pharmacol 8(10):738\u2013747. https:\/\/doi.org\/10.1002\/psp4.12461","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10034_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1208\/s12248-014-9640-5","volume":"16","author":"L Li","year":"2014","unstructured":"Li L, Gardner I, Dostalek M, Jamei M (2014) Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J 16(5):1097\u20131109. https:\/\/doi.org\/10.1208\/s12248-014-9640-5","journal-title":"AAPS J"},{"issue":"6","key":"10034_CR40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3324\/haematol.2020.265868","volume":"107","author":"JI Nishimura","year":"2022","unstructured":"Nishimura JI, Ando K, Masuko M, Noji H, Ito Y, Mayer J, Griskevicius L, Bucher C, Mullershausen F, Gergely P, Rozenberg I, Schubart A, Chawla R, Rondeau JM, Roguska M, Splawski I, Keating MT, Johnson L, Danekula R, Bagger M, Watanabe Y, Haraldsson B, Kanakura Y (2022) Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica 107(6):1483\u20131488. https:\/\/doi.org\/10.3324\/haematol.2020.265868","journal-title":"Haematologica"},{"key":"10034_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jim.2014.12.011","volume":"417","author":"JP Landry","year":"2015","unstructured":"Landry JP, Ke Y, Yu GL, Zhu XD (2015) Measuring affinity constants of 1450 monoclonal antibodies to peptide targets with a microarray-based label-free assay platform. J Immunol Methods 417:86\u201396. https:\/\/doi.org\/10.1016\/j.jim.2014.12.011","journal-title":"J Immunol Methods"},{"issue":"8","key":"10034_CR42","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/bcp.13970","volume":"85","author":"S Pan","year":"2019","unstructured":"Pan S, Yu H, Surti A, Cheng I, Marks SD, Brogan PA, Eleftheriou D, Standing JF (2019) Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. Br J Clin Pharmacol 85(8):1790\u20131797. https:\/\/doi.org\/10.1111\/bcp.13970","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10034_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.30","volume":"3","author":"X Chen","year":"2014","unstructured":"Chen X, Hickling TP, Vicini P (2014) A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model. CPT: Pharmacometrics & Systems Pharmacology 3(9):e133. https:\/\/doi.org\/10.1038\/psp.2014.30","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"9","key":"10034_CR44","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/psp4.70080","volume":"14","author":"P Gupta","year":"2025","unstructured":"Gupta P, Ryman JT, Jawa V, Meibohm B (2025) Mechanism-based modeling approaches to quantify the effect of immunogenicity on the pharmacokinetics of therapeutic proteins in drug development. CPT Pharmacometrics Syst Pharmacol 14(9):1431\u20131441. https:\/\/doi.org\/10.1002\/psp4.70080","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10034_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070845","author":"P Gupta","year":"2025","unstructured":"Gupta P, Ryman JT, Jawa V, Meibohm B (2025) A semi-mechanistic mathematical model of immune tolerance induction to support preclinical studies of human monoclonal antibodies in rats. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17070845","journal-title":"Pharmaceutics"},{"issue":"3","key":"10034_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1423-0410.2003.00278.x","volume":"84","author":"MA Alyanakian","year":"2003","unstructured":"Alyanakian MA, Bernatowska E, Scherrmann JM, Aucouturier P, Poplavsky JL (2003) Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 84(3):188\u2013192. https:\/\/doi.org\/10.1046\/j.1423-0410.2003.00278.x","journal-title":"Vox Sang"},{"issue":"6","key":"10034_CR47","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik M, Lin K (2018) Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci 11(6):540\u2013552. https:\/\/doi.org\/10.1111\/cts.12567","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10034_CR48","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4161\/mabs.29095","volume":"6","author":"JP Davda","year":"2014","unstructured":"Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs J (2014) A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. MAbs 6(4):1094\u20131102. https:\/\/doi.org\/10.4161\/mabs.29095","journal-title":"MAbs"},{"issue":"5","key":"10034_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S (2023) Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol 18(5):667\u2013684. https:\/\/doi.org\/10.1007\/s11523-023-00989-z","journal-title":"Target Oncol"},{"key":"10034_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.855743","volume":"13","author":"L Bansal","year":"2022","unstructured":"Bansal L, Nichols EM, Howsmon DP, Neisen J, Bessant CM, Cunningham F, Petit-Frere S, Ludbrook S, Damian V (2022) Mathematical modeling of complement pathway dynamics for target validation and selection of drug modalities for complement therapies. Front Pharmacol 13:855743. https:\/\/doi.org\/10.3389\/fphar.2022.855743","journal-title":"Front Pharmacol"},{"issue":"12","key":"10034_CR51","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1046\/j.1600-6135.2003.00273.x","volume":"3","author":"HM Gebel","year":"2003","unstructured":"Gebel HM, Bray RA, Nickerson P (2003) Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3(12):1488\u20131500. https:\/\/doi.org\/10.1046\/j.1600-6135.2003.00273.x","journal-title":"Am J Transplant"},{"issue":"11","key":"10034_CR53","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood.V110.11.2371.2371","volume":"110","author":"J Li","year":"2007","unstructured":"Li J, Levi M, Charoin JE, Frey N, Kheoh T, Ren S, Woo M, Joshi A, Valente N, Jumbe NS (2007) Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin\u2019s Lymphoma (NHL) Patients. Blood 110(11):2371. https:\/\/doi.org\/10.1182\/blood.V110.11.2371.2371","journal-title":"Blood"},{"issue":"4","key":"10034_CR54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/01.tp.0000112934.12622.2b","volume":"77","author":"CA Vieira","year":"2004","unstructured":"Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics. Transplantation 77(4):542\u2013548. https:\/\/doi.org\/10.1097\/01.tp.0000112934.12622.2b","journal-title":"Transplantation"},{"issue":"5","key":"10034_CR55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/icb.1997.69","volume":"75","author":"DA Fulcher","year":"1997","unstructured":"Fulcher DA, Basten A (1997) B cell life span: a review. Immunol Cell Biol 75(5):446\u2013455. https:\/\/doi.org\/10.1038\/icb.1997.69","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10034_CR56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity 8(3):363\u2013372. https:\/\/doi.org\/10.1016\/s1074-7613(00)80541-5","journal-title":"Immunity"},{"issue":"3","key":"10034_CR57","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1346-8138.2009.00796.x","volume":"37","author":"Y Aoyama","year":"2010","unstructured":"Aoyama Y (2010) What\u2019s new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. J Dermatol 37(3):239\u2013245. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00796.x","journal-title":"J Dermatol"},{"issue":"7","key":"10034_CR58","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1111\/bcp.14712","volume":"87","author":"JL Lee","year":"2021","unstructured":"Lee JL, Mohd Saffian S, Makmor-Bakry M, Islahudin F, Alias H, Noh LM, Ismail IH, Mohamed Shah N (2021) Population pharmacokinetic modelling of intravenous immunoglobulin in patients with predominantly antibody deficiencies. Br J Clin Pharmacol 87(7):2956\u20132966. https:\/\/doi.org\/10.1111\/bcp.14712","journal-title":"Br J Clin Pharmacol"},{"issue":"A","key":"10034_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109331","volume":"113","author":"Z Li","year":"2022","unstructured":"Li Z, Follman K, Freshwater E, Engler F, Yel L (2022) Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies. Int Immunopharmacol 113(A):109331. https:\/\/doi.org\/10.1016\/j.intimp.2022.109331","journal-title":"Int Immunopharmacol"},{"key":"10034_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111447","volume":"128","author":"Z Li","year":"2024","unstructured":"Li Z, Follman K, Freshwater E, Engler F, Yel L (2024) Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. Int Immunopharmacol 128:111447. https:\/\/doi.org\/10.1016\/j.intimp.2023.111447","journal-title":"Int Immunopharmacol"},{"key":"10034_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/282989","volume":"2012","author":"JJ Xiao","year":"2012","unstructured":"Xiao JJ (2012) Pharmacokinetic models for FcRn-mediated IgG disposition. J Biomed Biotechnol 2012:282989. https:\/\/doi.org\/10.1155\/2012\/282989","journal-title":"J Biomed Biotechnol"},{"issue":"18","key":"10034_CR62","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","volume":"9","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Mohan M, Rejeski K, Puliafito BR, Cirstea DD, Kaur G, Midha S, McCaughan GJ, Kumar NM, Mehra N, Bagal B, Raje NS (2025) Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Adv 9(18):4720\u20134726. https:\/\/doi.org\/10.1182\/bloodadvances.2025016490","journal-title":"Blood Adv"},{"issue":"1","key":"10034_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34804-6","volume":"13","author":"HW Kim","year":"2023","unstructured":"Kim HW, Lee J, Heo SJ, Kim BS, Huh KH, Yang J (2023) Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients. Sci Rep 13(1):7682. https:\/\/doi.org\/10.1038\/s41598-023-34804-6","journal-title":"Sci Rep"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10034-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:25:57Z","timestamp":1786375557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10034-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10034"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10034-x","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G. is currently employed by Bristol Myers Squibb. V.S.A. is a former employee of Johnson & Johnson and is currently employed by GSK; he may also own stock in both companies. The authors declare no other conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32"}}